| 摘要 |
The present invention relates to novel therapeutic protein useful in the treatment of diseases, in particular in human subjects. The results of the inventor strongly support the use of soluble IL-18Ralpha in the treatment of diseases such as autoimmune or demyelinating disease, in particular Multiple Sclerosis (MS). Accordingly, the invention provides soluble IL-18Ralpha for use in the treatment of autoimmune or demyelinating disease, in particular MS. The invention also provides methods of treating, preventing or ameliorating the symptoms of autoimmune or demyelinating disease, in particular MS, in a subject, preferably a human subject, by administering a therapeutically effective amount of said soluble IL-18Ralpha to the subject.
|
